Related Experiment Videos

Gentamicin and albumin-bilirubin binding. An in vivo study

The Journal of Pediatrics
|September 1, 1976
PubMed

Insights

Gentamicin does not affect bilirubin levels or binding in newborns. This study confirms that gentamicin is safe for neonatal use, showing no impact on bilirubin-albumin binding capacity.

Area of Science:

  • Neonatal pharmacology
  • Clinical toxicology
  • Pediatric drug safety

Background:

  • Jaundice is common in newborns, often treated with phototherapy or medication.
  • Gentamicin is an antibiotic frequently used in neonatal intensive care units.
  • Concerns exist regarding potential drug interactions affecting bilirubin metabolism in infants.

Purpose of the Study:

  • To investigate the in vivo effect of gentamicin on bilirubin-albumin binding in newborn infants.
  • To determine if serum gentamicin concentrations correlate with changes in bilirubin levels or binding capacity.
  • To provide clinical data supporting the safety of gentamicin in neonates regarding bilirubin metabolism.

Main Methods:

  • Ten newborn infants received intramuscular gentamicin.
  • Serum samples were collected over a 12-hour postinjection period.
  • Measurements included total binding capacity of serum albumin for bilirubin and serum bilirubin concentrations.

Main Results:

  • No significant changes in total binding capacity of serum albumin for bilirubin were observed.
  • Serum bilirubin levels remained stable throughout the 12-hour observation period.
  • No correlation was found between serum gentamicin concentrations and bilirubin-albumin binding or bilirubin levels.

Conclusions:

  • Gentamicin administration does not alter bilirubin-albumin binding in newborn infants.
  • The findings support in vitro data suggesting gentamicin's safety concerning bilirubin metabolism.
  • Gentamicin can be safely used in neonates without compromising bilirubin clearance mechanisms.

Related Concept Videos